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Abstract 
Background: Lung cancer is the leading cause of cancer related deaths and Malignant Pleural Effusion (MPE) is a 
frequent complication. Current therapies suffer from lack of efficacy in a great percentage of cases, especially when 
cancer is diagnosed at a late stage. Moreover patients’ responses vary and the outcome is unpredictable. Therefore, 
the identification of patients who will benefit most of chemotherapy treatment is important for accurate prognos-
tication and better outcome. In this study, using malignant pleural effusions (MPE) from non-small cell lung cancer 
(NSCLC) patients, we established a collection of patient-derived Adenocarcinoma cultures which were characterized 
for their sensitivity to chemotherapeutic drugs used in the clinical practice.
Methods: Tumor cells present in MPEs of patients with NSCLC were isolated by density gradient centrifugation, 
placed in culture and genotyped by next generation sequencing. In a subset of cases patient derived xenografts 
(PDX) were obtained upon tumor cell inoculation in rag2/IL2 knock-out mice. Isolated primary cultures were charac-
terized and tested for drug sensitivity by in vitro proliferation assays. Additivity, antagonism or synergy for combinato-
rial treatments were determined by analysis with the Calcusyn software.
Results: We have optimized isolation procedures and culture conditions to expand in vitro primary cultures from 
Malignant Pleural Effusions (MPEs) of patients affected by lung adenocarcinomas, the most frequent form of non 
small cell lung cancer. Using this approach we have been able to establish 16 primary cultures from MPEs. Cells were 
banked at low passages and were characterized for their mutational pattern by next generation sequencing for most 
common driver mutations in lung cancer. Moreover, amplified cultures were shown to engraft with high efficiency 
when injected in immunocompromised mice. Cancer cell sensitivity to drugs used in standard chemotherapy 
regimens was assessed either individually or in combination. Differential chemosensitivity and different mutation 
profiles were observed which suggests that this isolation method could provide a platform for predicting the efficacy 
of chemotherapy in the clinical setting. Most importantly for six patients it was possible to establish a correlation 
between drug response in vitro and response to therapy in the clinic.
Conclusions: Results obtained using primary cultured cells from MPEs underscore the heterogeneity of NSCLC 
in advanced stage as indicated by drug response and mutation profile. Comparison of data obtained from in vitro 
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Background
Lung cancer is the leading cause of cancer-related death 
around the world. Non-small cell lung cancer (NSCLC) 
comprises about 80 % of all lung malignancies. More than 
half of NSCLC patients are diagnosed when tumor is at a 
late stage (III B and IV) and the only option is systemic 
chemotherapy [1, 2]. However, 5-year survival rate of 
these patients remains below 10 %. This low survival rate 
is due in large part to heterogeneity of tumor response to 
chemotherapy and lack of biomarkers or assays to guide 
the choice of the best chemotherapy. Ideally to be most 
effective therapy should be designed after careful assess-
ment of the in  vitro and/or in  vivo chemosensitivity of 
patient’s tumor cells against a repertoire of potential 
therapeutic agents in order to select the best option for 
each patient on a personalized basis [3–6]. Furthermore, 
our increasing knowledge of the complex repertoire of 
actionable mutations occurring in genes driving uncon-
trolled tumor cell growth, combined with the develop-
ment of efficient and low cost next generation sequencing 
technologies open up new opportunities for therapeutic 
intervention to be exploited in the future by genomic 
driven clinical trials [7].
Although pursued for many years, the translation of 
in  vitro assay-informed therapy in clinical practice has 
been hampered by various technical problems, including 
the requirement of a high technical skill level, the large 
number of required tumor cells, and the long turna-
round time [8, 9]. Consequently, treatment schedules and 
agents used in monotherapy or combination chemother-
apy are still determined on the basis of the result of large 
clinical trials which do not take into account interpatient 
heterogeneity in response to chemodrugs. Hence, no reli-
able method has been developed to efficiently determine 
the best chemotherapy on an individualized basis.
The propagation of patients’ tumor cells is considered 
to be a source of material most closely related to the orig-
inal tumor. In recent years great emphasis has been given 
to the possibility to transplant and propagate human 
tumors through serial passages in immunodeficient 
mice devoid of B, T and NK cells [10–12]. These patient 
derived xenografts (PDX) have been shown to be predic-
tive of clinical outcome compared to conventional, cell 
line derived xenograft (CDX) models, in particular when 
therapeutic compounds were tested at clinically rel-
evant doses (CRDs) [10, 13–18]. However, engraftment 
and tumor growth rates usually do not allow to assess 
in a timely manner patients’ chemosensitivity in order 
to instruct therapeutic decisions. PDX tumors are usu-
ally obtained from biopsies or resected primary tumors 
but this material is often of limited availability or cellular 
vitality, is not adequately preserved, and this accounts for 
the low engraftment rates observed in literature [19–21]. 
Moreover, tumor cells from sites other than the primary 
tumor, may increase our understanding of tumor evolu-
tion or tumor characteristics [22]. Therefore alternative 
sources of tumor cells are highly desirable in order to 
obtain sufficient material for chemosensitivity studies.
We have previously shown that tumor cells from pleural 
effusions of patients with NSCLC can be readily isolated 
and expanded in culture with high efficiency [23]. MPE is 
manifesting as a metastatic lesion and an advanced dis-
ease setting with poor prognosis. We showed that MPE-
derived cell cultures achieve efficient tumor engraftment 
in recipient NOD/SCID mice, also upon inoculation of 
small number of cells, thus suggesting indirectly the pres-
ence of tumor initiating cells. Furthermore these cells were 
shown to be a promising system for the study of epithelial-
to-mesenchimal transition (EMT) [24] and of the mecha-
nisms responsible for resistance to EGFR inhibitors [25].
In the present study, we have analyzed a panel of low 
passages MPE-derived tumor cultures from NSCLC 
patients for a series of parameters including genetic alter-
ations, rate of cell growth and chemosensitivity to chem-
otherapeutic agents currently used for the therapy of lung 
cancer in  vitro. A subset of cultures was used to derive 
PDX models. Finally we tried to assess whether in vitro 
chemosensitivity to drugs may correlate with clinical 
responses. Our data, although limited to a small number 
of cases, suggest that MPE-derived tumor cultures could 
serve as a valuable tool for screening for sensitivity to 
chemotherapeutic agents and for genetic profiling useful 
to select the most effective therapy regimen.
Methods
Patients
A total of 16 patients (10 males and 6 females; mean age 
72 + 7 years; clinical stage was determined according to 
assays with patients’ responses to therapy leads to the conclusion that this strategy may provide a potentially useful 
approach for evaluating individual chemosensitivity profile and tailor the therapy accordingly. Furthermore, combin-
ing MPE-derived primary cultures with their genomic testing allows to identify patients eligible to trials with novel 
targeted agents.
Keywords: Malignant pleural effusions, NSCLC primary cultures, PDX, Next generation sequencing, In vitro 
chemosensitivity
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the TNM classification) with histologically or cytologi-
cally confirmed diagnosis of adenocarcinoma of the lung 
complicated with malignant pleural effusion were stud-
ied. Therefore, all the patients were considered to be with 
a stage IV of disease. Tumor specimens were obtained 
for diagnosis or therapeutic indications. The study was 
approved by S. Andrea Hospital Ethics Committee 2010 
(504/10) and all patients agreed to participate to the 
study signing an informed consent form.
MPE primary cultures
Primary cultures were obtained as previously described 
[23]. Briefly, pleural fluids (200–1000 ml) were obtained 
by thoracentesis and collected aseptically in heparinized 
(10  U/ml) bottles/tubes. Samples were centrifuged at 
300 g for 10 min, at 4 °C, and cell pellet was resuspended 
in 10 % FCS-RPMI (Invitrogen) or 1 % BSA/2 mM EDTA/
PBS. Viability was determined by Trypan Blue exclusion 
dye and cell suspension was sedimented on Oncoquick 
(Greiner Bio One) gradient or Ficoll PLUS after the addi-
tion of RosetteSep cocktail (Stemcell). During the cen-
trifugation step the cells were separated according to 
their different buoyant densities. The denser fluid com-
ponents such as erythrocytes and leucocytes migrate into 
the lower phase through the bottom of the tube. The less 
dense cell fraction, including tumor cells, were enriched 
at the interphase layer formed between the plasma and 
the separation medium in the phase. After a harvesting 
and washing step, tumor cells were cultured in 10 % FCS-
RPMI to obtain primary adherent cultures.
Multiple gene mutation analysis by next generation 
sequencing
Tumor samples were analyzed with the Ion AmpliseqTM 
Colon and Lung Cancer Panel (Life Technologies) using 
Ion Torrent semiconductor sequencing as previously 
described [26].
Whole exome sequencing
Next generation sequencing experiments, including 
quality control samples, were performed by Genomix-
4life S.R.L. (Baronissi, Salerno, Italy). Indexed libraries 
were prepared from 250  ng/ea DNA, after sharing with 
a Bioruptor sonicator, using the SureSelect Human All 
Exon kit (50 Mb; Agilent Technologies) according to the 
manufacturer’s instructions. Libraries were quantified 
using the Agilent 2100 Bioanalyzer (Agilent Technolo-
gies) and pooled in equimolar amounts to final concen-
tration of 2 nM. Pooled samples were then subjected to 
cluster generation and sequencing using an Illumina 
HiSeq 2500 System (Illumina) in a 100 bp paired-end for-
mat at a final concentration of 8 pmol. The raw sequence 
files generated in fastq format underwent quality control 
analysis using FastQC (http://www.bioinformatics.babra-
ham.ac.uk/projects/fastqc/).
The sequence reads were mapped against human 
genome (Homo sapiens Ensembl GRCh37, hg19) using 
Burrows-Wheeler Alignment (BWA version 0.7.7) soft-
ware [27]. Sequence variations were detected by The 
Genome Analysis Toolkit (GATK; Broad Institute, Cam-
bridge, MA, USA) software [28].
The Database for Annotation, Visualization and Inte-
grated Discovery (DAVID; http://david.abcc.ncifcrf.gov) 
was used to perform functional annotation analysis of 
enriched gene ontology (GO) terms and KEGG path-
ways. Statistical significance was evaluated with a modi-
fied Fisher’s exact test (EASE score) and GO BIOCARTA 
and KEGG terms with P values  ≤0.05 were considered 
significant.
Chemicals and reagents
Cisplatin, carboplatin, docetaxel, vinorelbine, gem-
citabine, gefitinib and erlotinib were obtained from 
SellekChem.
Cytotoxicity assays
To determine effects on proliferation, MPE primary 
cultures were treated in triplicate with increasing con-
centrations of anticancer drugs for 72  h. Inhibition of 
cell proliferation was measured by colorimetric WST-1 
assay. MPE primary cultures were plated in triplicate in 
96-well flat-bottom plates at a density of 2000 cells/well 
and incubated overnight. Anticancer drugs were added 
at various concentrations in triplicates to the media and 
cells were cultured for an additional 72 h. At the end of 
the experiment, cell survival was determined by WST-1 
assay (Roche) according to the manufacturer’s instruc-
tions. Absorbance was measured by spectrophotometer 
at a wavelength of 450 nm and viability was determined 
as percent of control cells (cells treated with the vehicle 
alone were defined as 100  % viable). Viability data were 
used to calculate EC50, concentration of agent at which 
the cell growth is inhibited by 50  %. EC50 values were 
determined by GraphPad (prism) and data points are 
presented as the average value ±  the standard deviation 
(SD).
Evaluation of drug combinations
To determine if the antitumor effects obtained with dif-
ferent drug combinations were synergistic, we calculated 
the combination index (CI) according to the Chou-Tala-
lay method using Calcusyn software (Biosoft, Cambridge, 
UK). (CI> 1, antagonism; CI  =   1, additive effect; CI < 1, 
synergism). Since the Chou-Talalay model calls for cyto-
toxic agents to be used at a fixed dose ratio, we chose to 
use drug combination at equipotent ratio (ratio of EC50). 
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Cells were treated with a combination that is four- to 
eightfold higher than the EC50, and used 1:3 serial dilu-
tions of the highest concentration combination to gen-
erate the dose-response curve, in parallel each single 
agent in the combination was tested alone in the same 
manner. Cells were treated for 72 h and at the end of the 
experiment, cell survival was determined by WST-1 assay 
(Roche) according to the manufacturer’s instructions.
Tumor engraftment studies
All studies have been performed in accordance with 
“Directive 2010/63/EU on the protection of Animals 
used for scientific purposes” and made effective in Italy 
by the Legislative Decree DLGS 26/2014. 6- to 8-weeks 
old Rag2/II2rg Double Knockout (Taconic) were uti-
lized. After 1 week of acclimation they were housed five 
to a plastic cage and fed on basal diet (4RF24, Mucedola 
S.r.l.) with water ad  libitum, in an animal facility con-
trolled at a temperature of 23 ± 2 °C, 60 ± 5 % humidity, 
and with a 12  h light and dark cycle. All animal proto-
cols used for this study were reviewed and approved by 
the Animal Welfare Body Takis/Plaisant. Animals were 
euthanized by cervical dislocation at the end of the study 
or when severe signs of suffering were observed. Before 
injection, cells were washed once in PBS and their pellet 
was resuspended in 50 % RGF matrigel (BD Biosciences) 
solution in Medium 199 and injected in the right flank 
of the mice in 200 µl volume/mouse. 1 × 106 or 5 × 106 
cells/mouse were injected for a total of 4–5 mice/primary 
culture. Tumor growth was monitored weekly by caliper 
measurement and tumor volume was determined by the 
formula (D × d2)/2, where D was the longest diameter 
of the tumor. The tumor doubling time (DT) in days was 
estimated from the log linear tumor growth during the 
exponential phase (range, 100–1000 mm3).
Results and Discussion
Mutational analysis of MPE derived cultures reveals a high 
degree of heterogeneity
We established sixteen MPE-derived cultures, each one 
from sixteen different patients affected by adenocar-
cinoma (AdenoCa) of the lung. In order to minimize 
adaptation in cell culture that may lead to selection of 
cell subpopulations with particular growth advantage we 
tried to work in the majority of cases with early passage 
cultures from p2 to p7. Exceptions were PE d/10, PE e/10 
and PE o/11 for which the earliest passage available for 
this study was p10. DNA was extracted as described in 
the methods section and subjected to Next Generation 
Sequencing (NGS) using the Ion AmpliseqTM Colon 
and Lung Cancer Panel (Life Technologies) targeting 500 
hotspot regions in 22 known driver genes in lung cancer. 
The results reported in Table 1 show as expected a highly 
heterogeneous pattern of mutations which reproduces 
the known high degree of heterogeneity of AdenoCa of 
the lung [29].
Interestingly, in our small sample we observed in sev-
eral cases a mutation frequency similar to that reported 
by TCGA, namely KRAS 37.5 % vs 32.2; BRAF mutations 
6 vs 6  %; MET 6 vs 4.3  %. TP53 mutations were unex-
pectedly low (18.75 vs 40 %). KRAS and EGFR mutations 
never occurred in the same samples. Activating EGFR 
mutations were detected in 31  % of cases vs 11.3  % in 
TCGA. This is in line with previous reports that showed 
an increased frequency of EGFR mutation in malignant 
pleural effusions vs tumor tissue [30]. Importantly in 3 
out of 5 cases of activating EGFR mutations (all Exon 19 
deletions) we observed the simultaneous presence of the 
gatekeeper T790  M mutation which confers resistance 
to TKIs although none of these patients was previously 
treated with EGFR TKIs. The presence of a pre-existing 
gatekeeper T790  M mutation together with activating 
EGFR mutations has already been reported at variable 
frequency depending upon the DNA sequencing meth-
odology and has been shown to affect time to disease 
progression after TKI therapy when mutation frequency 
is above 3 % as in our cases (see Table 1) [31, 32]. Finally, 
we also observed a high rate (12.5 %) of mutations in the 
tumor suppressor STK11 gene.
In several cases mutations were detected at low fre-
quencies (between 10 and 20  % and in any case sig-
nificantly below 50  %), which suggests the existence 
of a heterogeneous populations of cells. This has been 
reported before in colorectal cancer [33, 34], breast can-
cer [35], and lung cancer [36, 37].
Overall, using this small panel of 22 genes it was pos-
sible to identify actionable mutations in driver genes in 
a large proportion of cases. This may provide new ther-
apeutic options for this type of patients if this informa-
tion is used to conduct genomic driven trials with new 
targeted agents.
We also determined the EC50 values for EGFR TKIs 
gefitinib and erlotinib for all 16 cell cultures (Fig. 1). The 
relative pattern of sensitivity was similar but not identi-
cal. The vast majority of cultures showed an intermedi-
ate to high degree of resistance to these drugs, also in 
the presence of EGFR sensitizing mutations, with the 
only exception of r/11 (one of the two cultures bear-
ing the presence of the Exon19 deletion in EGFR with-
out the coexistence of the resistance mutation T790 M) 
which showed a good sensitivity to both gefitinib and 
erlotinib. However, the other culture with the same 
NGS mutational pattern, namely v/11 was highly resist-
ant to both drugs, which suggests that chemosensitiv-
ity may be affected by other mutational or epigenetic 
changes not revealed by this analysis. The three cultures 
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with coexisting Exon19 deletion and T790  M muta-
tions, p/11, s/11 and u/11, were as expected intermedi-
ate to highly resistant to both drugs. Overall however, 
the NGS mutational pattern reported Table  1 did not 
allow to predict chemosensitivity to both gefitinib and 
erlotinib shown in Fig.  1. This was also the case for 
the six cultures bearing KRAS mutations (d/10, e/10, 
h/11, i/11, o/11 and b/12) alone or in combination 
with others. Although it is interesting to observe that 
within this group the more sensitive cultures were those 
bearing mutations in PIK3CA, their response to drugs 
spanned the entire range.
In conclusion, although we are cognizant of the small 
number of cases analyzed, in our system drug sensitivity 
to TKIs could not be entirely anticipated by NGS data. 
This supports two important concepts: (a) sensitivity 
Table 1 Mutations identified in MPE primary cultures
* nonsense mutation
KRAS EGFR PIK3CA BRAF MET TP53 STK11 In vivo
Exon19del T790 M
PE d/10
(p10)
46 %
p.G12V
(c. 35 G>T)
No
PE e/10
(p10)
87.9 %
p.Q61H
(c.183 A>C)
31.6 %
p. T1010I
(c. 3029 C>T)
Yes
PE b/11
(p3)
53.5 %
p.V600E
(c.1799 T>A)
Yes
PE g/11
(p6)
Yes
PE h/11
(p4)
43.1 %
p.G12D
(c. 35 G>A)
No
PE i/11
(p5)
37.2 %
p.Q61 K
(c.181 C>A)
100 %
p.R175H
(c.524 G>A)
Yes
PE n/11
(p3)
Yes
PE o/11
(p10)
98.8 %
p.Q61H
(c.183 A>T)
54.2 %
p.E545 K
(c.1633 G>A)
100 %
p.Q37*
(c.109 C>T)
No
PE p/11
(p7)
100 %
p.E746_A750del
(c.2235_2249del15)
17.2 %
p.T790 M
(c.2369 C>T)
100 %
p.R248Q
(c.743 G>A)
No
PE r/11
(p5)
47 %
p.E746_A750del
(c.2235_2249del15)
No
PE s/11
(p3)
42 %
p.E746_A750del
(c.2235_2249del15)
15 %
p.T790 M
(c.2369 C>T)
14.3 %
p.S241F
(c.722 C>T)
Yes
PE u/11
(p6)
49 %
p.E746_A750del
(c.2235_2249del15)
11.3 %
p.T790 M
(c.2369 C>T)
Yes
PE v/11
(p2)
57 %
p.E746_A750del
(c.2235_2249del15)
Yes
PE z/11
(p4)
Yes
PE b/12
(p4)
100 %
p.Q61H
(c.183 A>C)
49.1 %
p.E545 K
(c.1633 G>A)
100 %
p.Q37*
(c.109 C>T)
Yes
PE f/13
(p3)
No
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to TKIs may be strongly affected by additional genetic 
or epigenetic changes not revealed by our present NGS 
panel; (b) empirical determination of drug sensitivity is 
an added value to predict drug sensitivity in the clinic.
Whole exome analysis reveals a pattern of mutations 
affecting distinct signaling and metabolic pathways
To identify the metabolic pathways affected in MPE-
derived cultures, we performed whole exome sequencing 
on five randomly chosen samples, b/12, n/11, o/11, s/11 
and u/11 which taken together well represent the dif-
ferential degree of sensitivity to gefitinib and erlotinib. 
This analysis generated an average number of mappable 
sequence data equal to 55.19  ±  21.40  Gb (Additional 
file 1: Table S1). A percentage higher than 99.5 % of the 
total reads produced was mapped to the reference human 
coding exome (Homo sapiens Ensembl GRCh37, hg19). 
From this amount of data, GATK version 3.3-3 identi-
fied an average of 219,178  ±  57,043 genetic variants, 
among which 21,220 ±  349 exomic and splice site type 
and 9830 ± 159 non-synonymous variants. Focusing on 
two samples having the same mutated genes by targeted 
resequencing (see previous paragraph), b/12 and o/11, it 
is possible to underline that they have a total number of 
variants equal to 20,963 and 21,499 among which 10,214 
and 10,499 non-synonymous variants respectively. Then 
we evaluated also the total number of shared non-synon-
ymous variants among the five MPE-derived cultures that 
resulted to be 4060 in 2573 different genes. The common 
mutations were distributed through the whole genome 
0,0
5,0
10,0
15,0
20,0
EC
50
 [u
M
]
Gefinib
0,0
5,0
10,0
15,0
20,0
25,0
30,0
EC
50
 [u
M
]
Erlonib
Fig. 1 Sensitivity of primary cultured MPE tumor cells to gefitinib and erlotinib
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but higher frequency were found in chromosomes 1, 11 
and 19 (Additional file 2: Figure S1)
To investigate the possible biological and metabolic role 
of the mutated genes, we categorized them into enriched 
categories according to GO molecular function classifica-
tion and BIOCARTA and KEGG pathway analysis.
The top GO categories that resulted significantly enriched 
with a P value  ≤0.05 and that comprised a number of 
genes higher than 50 were: ion binding, calcium ion bind-
ing, peptidase activity, olfactory receptor activity, structural 
molecule activity, cytoskeletal protein binding, endopepti-
dase activity, carbohydrate binding and actin binding.
Moreover, to evaluate the enrichment in signaling 
pathways, we performed BIOCARTA and KEGG analy-
sis on the 2573 genes. The top 6 enriched pathways in 
BIOCARTA database were: B Lymphocyte Cell Surface 
Molecules, Monocyte and its Surface Molecules, Role of 
BRCA1, BRCA2 and ATR in Cancer Susceptibility, Regu-
lation of cell cycle progression by Plk3, Adhesion Mole-
cules on Lymphocyte, and Cells and Molecules involved 
in local acute inflammatory response (Fig. 2a). Among the 
genes involved in these pathways there are CD44, some 
integrins, BRCA1, BRCA2 and TP53. The top 7 enriched 
pathways in KEGG database were: Olfactory transduc-
tion, ECM-receptor interaction, Taste transduction, 
Complement and coagulation cascades, Focal adhesion, 
ABC transporters, and Tyrosine metabolism (Fig. 2b). In 
these different pathways we found involved the olfactory 
receptor family, the taste receptors, some coagulation 
and complement factors, a2-microglobulin, ATP-binding 
cassette family, alcohol dehydrogenases, collagen type 
family, integrins, laminins, ERBB2, protein kinase C and 
cyclin D3.
In vivo tumor growth often leads to selection of cell 
populations with a different mutational pattern
Malignant pleural effusion is a poor prognostic factor 
for patients with lung cancer and the treatment is merely 
palliative [38]. Patient-derived tumor xenograft (PDX) 
models have been established and increasingly used for 
preclinical studies of targeted therapies in recent years. 
However, PDX mouse models are difficult to obtain with 
low percentage of success [19] and in particular, patient-
derived non-small cell lung cancer (NSCLC) xenograft 
are relatively few in number and are limited in their 
degree of genetic characterization. We have character-
ized the isolated primary cultures for their ability to 
establish tumor xenograft in rag2-/Il2- double knock-out 
mice. Among the primary culture tested, more than 80 % 
of them were able to grow when injected s.c. establish 
subcutaneous xenografts. Moreover a great variability in 
latency time and doubling time was observed as shown in 
(Additional file 1: Table S2).
We extracted gDNA from tumors grown in PDX and 
carried out mutational analysis with the same NGS panel 
used for MPE-derived cells grown in vitro and the com-
parison of the pattern of mutations in the same samples 
between in vitro and in vivo is shown in Table 2.
It can immediately be appreciated that in vivo growth 
causes an overall increase in the frequency of mutations. 
Out of the 10 samples analyzed in parallel, only 3 (b/12, 
s/11 and i/11) maintain the same mutational pattern, with 
some differences in the abundance of cells with mutations 
between in vitro culture and PDX. In the remaining sam-
ples the pattern of mutations is dramatically different. In 
particular we can observe three major phenomena: (a) 
dramatic increase of TP53 mutations which now slightly 
exceed the frequency observed in TCGA (50 vs 40 %), (b) 
appearance of mutations in MPE-derived samples where 
no mutation had been detected in vitro (g/11, n/11), (c) 
disappearance of mutations present in the in vitro culture 
at low frequency and appearance of new mutations very 
often at high frequency.
This finding is of relevance because it suggests that 
some primary cultures are intrinsically highly hetero-
geneous in their composition and contain at very low 
percentages subclones carrying mutations undetectable 
by NGS. A dynamic adaptation takes place in the local 
Fig. 2 The 2573 mutated genes were categorized into enriched 
categories according to BIOCARTA (a) and KEGG (b) pathway analysis
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Table 2 Comparison of Mutations identified in MPE primary cultures and PDX
* nonsense mutation
KRAS EGFR PIK3CA BRAF MET TP53 STK11
Exon19del T790 M
PE e/10
(p10)
87.9 %
p.Q61H
(c.183 A>C)
31.6 %
p. T1010I
(c. 3029 C>T)
PE e/10
(PDX)
50.4 %
p.Q61H
(c.183 A>C)
49.2 %
p.E545 K
(c.1633 G>A)
44.5 %
p.Q37*
(c.109 C>T)
PE b/11
(p3)
53.5 %
p.V600E
(c.1799 T>A)
PE b/11
(PDX)
100 %
p.E746_A750del
(c.2235_2249del15)
15.2 %
p.T790 M
(c.2369 C>T)
97.6 %
p.R248Q
(c.743 G>A)
PE g/11
(p6)
PE g/11
(PDX)
75.5 %
p.Q61H
(c.183 A>C)
49.5 %
p.E545 K
(c.1633 G>A)
77.7 %
p.Q37*
(c.109 C>T)
PE i/11
(p5)
37.2 %
p.Q61 K
(c.181 C>A)
100 %
p.R175H
(c.524 G>A)
PE i/11
(PDX)
29.4 %
p.Q61 K
(c.181 C>A)
100 %
p.R175H
(c.524 G>A)
PE n/11 (p3)
PE n/11
(PDX)
27 %
p.Q61 K
(c.181 C>A)
100 %
p.R175H
(c.524 G>A)
PE s/11
(p3)
42 %
p.E746_A750del
(c.2235_2249del15)
15 %
p.T790 M
(c.2369 C>T)
14.3 %
p.S241F
(c.722 C>T)
PE s/11
(PDX)
100 %
p.E746_A750del
(c.2235_2249del15)
15.8 %
p.T790 M
(c.2369 C>T)
94.7 %
p.R248Q
(c.743 G>A)
PE u/11
(p6)
49 %
p.E746_A750del
(c.2235_2249del15)
11.3 %
p.T790 M
(c.2369 C>T)
PE u/11
(PDX)
92 %
p.E746_A750del
(c.2235_2249del15)
11.8 %
p.T790 M
(c.2369 C>T)
100 %
p.R248Q
(c.743 G>A)
PE v/11
(p2)
57 %
p.E746_A750del
(c.2235_2249del15)
PE v/11
(PDX)
87.5 %
p.E746_A750del
(c.2235_2249del15)
93.5 %
p.R248Q
(c.743 G>A)
PE z/11 (p4)
PE z/11
(PDX)
100 %
p.E746_A750del
(c.2235_2249del15)
14.2 %
p.T790 M
(c.2369 C>T)
98.8 %
p.R248Q
(c.743 G>A)
PE b/12
(p4)
100 %
p.Q61H
(c.183 A>C)
49.1 %
p.E545 K
(c.1633 G>A)
100 %
p.Q37*
(c.109 C>T)
PE b/12
(PDX)
65.7 %
p.Q61H
(c.183 A>C)
49 %
p.E545 K
(c.1633 G>A)
63 %
p.Q37*
(c.109 C>T)
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tumor microenvironment by which these subclones 
emerge, while others disappear. Based on these data we 
believe that combining genetic testing of both primary 
cultures and PDX-derived tumors may provide a more 
complete analysis of the spectrum of tumor mutations 
for this group of patients.
In vitro drug testing shows a high degree of differences 
in drug sensitivity in MPE‑derived cultures
MPE-derived primary cultures were analyzed for their 
sensitivity to different chemotherapeutic drugs used in 
conventional adenocarcinoma lung therapies, cisplatin, 
carboplatin, gemcitabine, vinolrebine and docetaxel. 
Chemodrugs were dosed as single agents and results 
showed a great variability in the response obtained 
(Fig. 3). Among the primary cultures PE v/11, i/11, n/11 
displayed cross resistance between most of the drugs 
tested. The majority of primary cultures was resistant to 
cisplatin (10 out of 16 of them showed an EC50 higher 
than 20  μM), while we observed a greater degree of 
sensitivity to carboplatin (only 5 out of 18 had an EC50 
higher than 20 μM). Carboplatin is a second generation 
platinum based compound with a different toxicity pro-
file than cisplatin. Apart from the toxicity profile, the two 
compounds have a very similar mechanism of action, 
inducing the same type of DNA-platinum adducts, and 
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Fig. 3 Sensitivity of primary cultured MPE tumor cells to chemotherapeutic drugs
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in terms of acquired resistance, usually show cross resist-
ance [39–41]. Reduced sensitivity to cisplatin may reside 
in an active drug efflux, like Copper efflux systems [42, 
43], that preferentially inhibits drug accumulation in the 
cells. Since several mechanisms of resistance to plati-
num-based compounds have been described [44], a final 
explanation cannot be provided without the execution of 
further studies.
In Fig. 4 is a heat map of single drug sensitivity to the 
five chemodrugs and to the two TKIs. This highlights 
that the two drugs for which there is a higher degree of 
sensitivity are gemcitabine and docetaxel. This is intrigu-
ing because these are usually not the first line treatment 
for this group of patients. Our findings therefore under-
score the importance of this type of in vitro chemosensi-
tivity studies to better instruct clinicians about the most 
efficacious therapy to use for this highly aggressive mani-
festation of disease.
In vitro assays lead to the identification of more effective 
synergistic combinations
Patients affected by NSCLC are usually treated with 
combination of drugs especially when diagnosed at late 
stage when there are no other treatment options [45, 46]. 
MPE-derived cultures were assessed for their sensitivity 
to combination of drugs mostly used in the clinical set-
tings and the results were evaluated by the Chou-Talalay 
method [47]. In Fig. 5a, b is shown as example the case of 
the MPE-derived r/11, where a strong synergism between 
cisplatin and gemcitabine could be observed. We con-
ducted a more systematic analysis of the combinatorial 
effect of vinolrebine, docetaxel and gemcitabine in 6 sam-
ples, g/11, n/11, p/11, r/11, s/11 and u/11 and the results 
are reported in Table  3. This analysis allowed to distin-
guish three distinct cases: additivity as in the case of g/11, 
antagonism in n/11 and p/11 and finally synergism in 
r/11, s/11 and u/11.
Vinorelbine Gemcitabine Docetaxel Gefinib Erlonib Carboplan Cisplan 
PE b/11 
PE b/12 
PE d/10 
PE e/10 
PE f/13 
PE g/11 
PE h/11 
PE i/11 
PE n/11 
PE o/11 
PE p/11 
PE r/11 
PE s/11 
PE u/11 
PE v/11 
PE z/11 
Vinorelbine 0-5nM 5-20nM >20nM 
Gemcitabine 0-5nM 5-20nM >20nM 
Docetaxel 0-5nM 5-20nM >20nM 
Gefinib 0-5uM 5-10uM >10uM 
Erlonib 0-5uM 5-10uM >10uM 
Carboplan 0-5uM 5-20uM >20uM 
Cisplan 0-5uM 5-20uM >20uM 
Fig. 4 Sensitivity heat map of PE primary cultures treated with single chemotherapeutic agent
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Therefore, we can conclude that MPE-derived cultures 
can be used to determine not only the degree of che-
mosensitivity to single drugs but also the degree of syn-
ergism to combinations of different chemotherapeutic 
agents.
Correlation between in vitro drug sensitivity and in vivo 
response to therapy
For six MPE-derived cultures for which we were able 
to assess in  vitro chemosensitivity we had informa-
tion about the first line therapy adopted and the clinical 
response. These data are shown in Table 4.
Two patients #1 and #2 from whom the g/11 and n/11 
cultures were derived respectively, were treated with the 
combination of cisplatin and vinolrebine. Patient #3 from 
whom p/11 was obtained, was treated with the combina-
tion of cisplatin and gemcitabine. Patients #4 and #6 from 
whom r/11 and u/11 were obtained were treated with 
the combination cisplatin + emcitabine +Bevacizumab. 
Finally patient #5 from whom s/11 was obtained was 
treated with the combination of cisplatin plus Taxotere.
Patients, #1, #4, #5 and #6 developed a partial response. 
This nicely correlated with the in vitro sensitivity of the 
corresponding cultures to at least one of the drug used 
in single treatments, i.e., g/11 (patient #1) to cisplatin; 
r/11 (patient #4) to cisplatin; s/11 (patient #5) to doc-
etaxel, u/11 (patient #6) to gemcitabine. Stable disease 
was observed in patient #3 where the corresponding p/11 
culture showed in  vitro sensitivity to both agents used 
in therapy cisplatin and gemcitabine. Finally, patient #2 
underwent progressive disease upon treatment with cis-
platin plus vinolrebine in line with the in vitro resistance 
of the corresponding n/11 culture to both agents.
Although the number of the patients enrolled is low, 
it is intriguing to observe that in  vitro chemosensitivity 
data match with clinical responses to therapy, which sug-
gests that the use of MPE-derived cultures may be help-
ful to predict in the future the best treatment for NSCLC 
patients with malignant pleural effusions. To confirm the 
significance of the acquired data a larger study with the 
appropriate number of patients would be required.
Conclusions
Malignant pleural effusion (MPE) is an unfavorable com-
plication of NSCLC. MPE severely restricts quality of life 
and has a poor prognosis. It is a metastatic manifesta-
tion of the disease caused by a combination of different 
processes such as inflammation, enhanced angiogen-
esis and vascular leakage. Response to therapies is usu-
ally poor because of relatively high tumor burden and 
chemoresistance. This last feature is linked to the pres-
ence of Cancer Stem Cells as we and others have shown 
in previous studies [23, 48, 49]. We believe that such an 
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Fig. 5 In vitro evaluation of cisplatin and gemcitabine co-treatment 
and determination of Combination Index (CI) for PE r/11. a Dose-
Effect curve and b Combination Index plot obtained by CalcuSyn 
software
Table 3 In vitro determination of  Combination Index (CI) 
of cisplatin combined with gemcitabine, or vinorelbine or 
taxotere
MPE culture Cisplatin combination CI
PE g/11 Vinorelbine 1
Gemcitabine 1
Docetaxel 1
PE n/11 Vinorelbine >1
Gemcitabine >1
Docetaxel >1
PE p/11 Vinorelbine >1
Gemcitabine >1
Docetaxel <1
PE r/11 Vinorelbine <1
Gemcitabine <1
Docetaxel <1
PE s/11 Vinorelbine <1
Gemcitabine <1
Docetaxel <1
PE u/11 Vinorelbine <1
Gemcitabine <1
Docetaxel 1
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aggressive disease requires a novel therapeutic strategy 
based on a personalized approach and that this should 
stem from the combination of genetic analysis of tumor 
cells as well as from accurate prediction of chemosensi-
tivity. In this study we have demonstrated the possibility 
to expand an initial population of MPE-derived tumor 
cells both through short term primary cultures as well 
as xenografts in order to carry out chemosensitivity 
assay and genetic characterization for most commonly 
altered driver genes in NSCLC. Data obtained highlight 
the extreme genetic heterogeneity of this disease but also 
the possibility to identify in the majority of cases muta-
tions in actionable genes. Therefore it should be possible 
to link this type of genetic characterization to patients’ 
enrollment in umbrella clinical trials with novel targeted 
agents [50]. Limiting our analysis to more conventional 
chemotherapies, a more feasible and immediate applica-
tion of our findings stems from the analysis of in  vitro 
chemosensitivity of MPE-derived cultures. We show 
here that sensitivity to chemotherapeutic agents is highly 
heterogeneous. However we also show that it is possible 
in all cases to identify a combination of drugs that have 
a synergistic effect in inhibiting tumor growth and that 
this combination is often not the most frequent combina-
tion used in the clinic. Finally, although limited to a very 
small number of cases we show that in vitro chemosen-
sitivity data match with patients’ response to therapy in 
the clinic. We believe that streamlining MPE sample pro-
cessing with in vitro chemosensitivity and genetic analy-
sis by NGS could open up new therapeutic options for 
this group of patients currently with limited therapeutic 
options and short term life expectancy. However one has 
to take into account that MPEs are present only in a small 
subset of the patients with advanced lung cancer, are a 
negative prognostic factor and strongly correlate to short 
patients’ survival. Thus, their clinical use could be limited 
by the extreme cancer burden and by the short life expec-
tancy of patients. Therefore it would be of much greater 
clinical impact to translate our approach to primary lung 
tumors and to expand in vitro and/or in vivo the usually 
very small amount of material obtained from biopsies in 
order to be able to fully assess chemosensitivity.
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